Oxford Nanopore recently announced that it has attracted a further £100M in funding. The latest investment round values Oxford Nanopore at £1.5B, with Singapore-based GIC, China Construction Bank International and Australian company Hostplus contributing to the offer. Since 2009, Oxford Nanopore has raised £499M through private placements, highlighting sustained VC and industry interest in the company’s disruptive sequencing technologies.
Oxford Nanopore started as an Oxford University spinout, receiving initial seed funding from IP Group in 2005. IP Group remains the company’s largest shareholder with a stake of 18.3%. Oxford Nanopore has stated that the most recent round of funding will be used to build a factory in Oxfordshire that will enable the company to meet the growing demand for its sequencing technologies.
** UPDATE: October 2018**
US multinational biotech company Amgen has made an equity investment of £50 million ($66 million) in Oxford Nanopore. An Amgen press release states that “the investment in Oxford Nanopore aligns with Amgen’s strategic focus on using human genetics to deliver new medicines to patients. Amgen subsidiary deCODE Genetics, a world leader in human genetics, uses Oxford Nanopore’s sequencing technologies to conduct genome research, including the identification and validation of new targets.”